2022 represented a landmark year for next-generation diabetes technologies. Here are the biggest stories from the past year.
Some companies picked up major regulatory nods. Others experienced major regulatory setbacks.
Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from, but here are 10 big ones that stood out:
Dexcom G7 receives FDA clearance
The long-awaited regulatory nod for Dexcom’s next-generation continuous glucose monitor (CGM) finally came in December.
Some suggested that San Diego-based Dexcom may pick up clearance as soon as summer 2022. However, a software change recommended by the FDA, plus COVID-19-related backlog, delayed proceedings.
Other Dexcom news in 2022:
- How Dexcom uses wearables to deliver differentiated diabetes management
- Dexcom launches Dexcom One offering overseas
- Dexcom launches NIL program for college athletes with diabetes
Get the full story at our sister site, Drug Delivery Business News.